Primary mediastinal large cell lymphoma (PMBL): Frontline treatment with autologous stem celltransplantation (ASCT). The GEL-TAMO experience

Hematological Oncology

Volumn 26, Issue 3, 2008, Pages 171-178

  Rodríguez, José ^a   Conde, Eulogio ^b   Gutiérrez, Antonio ^a   García, Juan Carlos ^c   Lahuerta, Juan José ^d   Varela, María Rosario ^e   Pérez, Catalina ^f   Albo, Carmen ^g   Caballero, María Dolores ^h  

^a HOSPITAL UNIVERSITARIO SON ESPASES   (Spain)

^b HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^c HOSPITAL DE CRUCES   (Spain)

^d HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^e HOSPITAL JUAN CANALEJO   (Spain)

^f Instituto de Investigación Sanitaria de Navarra   (Spain)

^g HOSPITAL XERAL CÍES   (Spain)

^h HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

Author keywords

Autologous stem cell transplantation; Frontline; Primary mediastinal large cell lymphoma

Indexed keywords

BUSULFAN; CARMUSTINE; CYCLOPHOSPHAMIDE; CYTARABINE; ETOPOSIDE; MELPHALAN;

ADULT; ALLOGENEIC PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CANCER RADIOTHERAPY; CANCER RELAPSE; CANCER RISK; CANCER SURVIVAL; CAUSE OF DEATH; COMBINATION CHEMOTHERAPY; DISEASE COURSE; DISEASE FREE SURVIVAL; FEMALE; HUMAN; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MEDIASTINUM CANCER; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; SCORING SYSTEM; TREATMENT FAILURE; TREATMENT OUTCOME; TREATMENT RESPONSE; WHOLE BODY RADIATION; ADOLESCENT; AGED; AUTOTRANSPLANTATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; MEDIASTINUM TUMOR; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; REGISTER;

ADOLESCENT; ADULT; AGED; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MEDIASTINAL NEOPLASMS; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROGNOSIS; REGISTRIES; TRANSPLANTATION, AUTOLOGOUS;

EID: 55249084185     PISSN: 02780232     EISSN: 10991069     Source Type: Journal    
DOI: 10.1002/hon.858     Document Type: Article

References (26)

1. Banks PM, Warnke RA. Mediastinal (thymic) large B-cell lymphoma. In Jaffe ES, Harris NL, Stein H (eds). World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Hematopoietic and Lymphoid Tissues. IARC Press: Lyon, 2001.
2. Abou-Elella AA, Weisenburger DD, Vose JK et al. Primary mediastinal large B-cell lymphoma: a clinicopathologic study of 43 patients from the Nebraska Lymphoma Study Group. J Clin Oncol 1999; 17(3): 784-790.
3. Cazals-Hatem D, Lepage E, Brice P, et al. Primary mediastinal large B-cell lymphoma. A. clinicopathologic study of 141 cases compared with 916 nonmediastinal large B-cell lymphomas, a GELA ("Groupe d'Etude des Lymphomes de I'Adulte") study. Am J Surg Pathol 1996; 20(7): 877-888.
4. Todeschini G, Secchi S, Morra E, et al. Primary mediastinal large B-cell lymphoma (PMLBCL): long-term results from a retrospective multicentre Italian experience in 138 patients treated with CHOP or MACOP-B/VACOP-B. Br J Cancer 2004; 90(2): 372-376.
5. Zinzani PL, Martelli M, Magagnoli M, et al. Treatment and clinical management of primary mediastinal large B-cell lymphoma with sclerosis: MACOP-B regimen and mediastinal radiotherapy monitored by (67)gallium scan in 50 patients. Blood 1999; 94(10): 3289-3293.
6. Zinzani PL, Martelli M, Bertini M, et al. Induction chemotherapy strategies for primary mediastinal large B-cell lymphoma with sclerosis: a retrospective multinational study on 426 previously untreated patients. Haematologica 2002; 87(12): 1258-1264.
7. Dunleavy K, Pittaluga S, Janik J, et al. Primary mediastinal large B-cell lymphoma (PMBL) outcome is significantly improved by the addition of Rituximab to dose adjusted (DA)-epoch and overcomes the need for radiation. Blood 2005; 106: 929.
8. Sehn LH, Donaldson J, Chhanabhai M, et al. Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. J Clin Oncol 2005; 23(22): 5027-5033.
9. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002; 346(4): 235-242.
10. Savage KJ, Monti S, Kutok JL, et al. The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma. Blood 2003; 102(12): 3871-3879.
11. Rosenwald A, Wright G, Leroy K, et al. Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma. J Exp Med 2003; 198(6): 851-862.
12. Harris NL, Jaffe ES, Stein H, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 1994; 84(5): 1361-1392.
13. A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 1993; 329(14): 987-994.
14. Rodriguez J, Cabanillas F, McLaughlin P, et al. A proposal for a simple staging system for intermediate grade lymphoma and immunoblastic lymphoma based on the 'tumor score'. Ann Oncol 1992; 3(9): 711-717.
15. Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI sponsored International Working Group. J Clin Oncol 1999; 17(4): 1244.
16. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-4481.
17. Peto R, Pike MC, Armitage P, et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples. Br J Cancer 1977; 35(1): 1-39.
18. Cox DR. Regression models and life-tables. J R Stat Soc 1972; 34: 187.
19. Sehn LH, Antin JH, Shulman LN, et al. Primary diffuse large B-cell lymphoma of the mediastinum: outcome following high-dose chemotherapy and autologous hematopoietic cell transplantation. Blood 1998; 91(2): 717-723.
20. Cairoli R, Grillo G, Tedeschi A, et al. Efficacy of an early intensification treatment integrating chemotherapy, autologous stem cell transplantation and radiotherapy for poor risk primary mediastinal large B cell lymphoma with sclerosis. Bone Marrow Transplant 2002; 29(6): 473-477.
21. Nademanee A, Molina A, O'Donnell MR, et al. Results of high-dose therapy and autologous bone marrow/stem cell transplantation during remission in poor-risk intermediate- and high-grade lymphoma: international index high and high-intermediate risk group. Blood 1997; 90(10): 3844-3852.
22. Savage KJ, Al-Rajhi N, Voss N, et al. Favorable outcome of primary mediastinal large B-cell lymphoma in a single institution: the British Columbia experience. Ann Oncol 2006; 17(1): 123-130.
23. Rodriguez J, Caballero MD, Gutierrez A, et al. Autologous stem-cell transplantation in diffuse large B-cell non-Hodgkin's lymphoma not achieving complete response after induction chemotherapy: the GEL/ TAMO experience. Ann Oncol 2004; 15(10): 1504-1509.
24. Constans M, Sureda A, Terol MJ, et al. Autologous stem cell transplantation for primary refractory Hodgkin's disease: results and clinical variables affecting outcome. Ann Oncol 2003; 14(5): 745-751.
25. Popat U, Przepiork D, Champlin R, et al. High-dose chemotherapy for relapsed and refractory diffuse large B-cell lymphoma: mediastinal localization predicts for a favorable outcome. J Clin Oncol 1999; 16(1): 63-69.
26. Romaguera JE, Rodriguez Diaz-Pavon J, Carias L, et al. Use of the international prognostic index and the tumor score to detect poor-risk patients with primary mediastinal large B-cell lymphoma: a study of 37 previously untreated patients. Leuk Lymphoma 1998; 28(3-4): 295-306.